Reaction
Bladder Catheterisation reporting signals
As of the last recalculation, Bladder Catheterisation appears in 954 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 26.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alemtuzumab | 23 | 26.6 | 26.6 |
| Rivastigmine | 14 | 16.4 | 16.5 |
| Vibegron | 6 | 16.4 | 16.4 |
| Amantadine | 11 | 15.7 | 15.7 |
| Apalutamide | 7 | 13.1 | 13.1 |
| Teriflunomide | 25 | 12.4 | 12.4 |
| Carbidopa And Levodopa | 26 | 12.3 | 12.3 |
| Rotigotine | 8 | 12.2 | 12.2 |
| Rasagiline Mesylate | 6 | 11.8 | 11.8 |
| Cladribine | 5 | 11.4 | 11.4 |
| Oxybutynin | 15 | 11.3 | 11.3 |
| Relugolix | 12 | 11.2 | 11.2 |
| Mirabegron | 18 | 10.3 | 10.3 |
| Dalfampridine | 31 | 9.7 | 9.7 |
| Levodopa | 5 | 9.1 | 9.1 |
| Riociguat | 13 | 8.8 | 8.8 |
| Pimavanserin Tartrate | 17 | 6.8 | 6.8 |
| Enzalutamide | 16 | 6.0 | 6.0 |
| Natalizumab | 48 | 6.0 | 6.0 |
| Leuprolide Acetate | 20 | 5.7 | 5.7 |